Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics Biotech reported strong clinical progress and a regulatory milestone for its REO 033 randomized trial evaluating pelareorep in combination with chemotherapy for second-line treatment of RAS-mutant microsatellite stable metastatic colorectal cancer. The company plans a Type D meeting with the FDA to discuss a registrational path by adding…